KDR and glioblastoma: This has been described following cediranib monotherapy in solid tumours; phase I study,24 acute myeloid leukaemia,25 glioblastoma,23 HCC,22 gastrointestinal stromal tumour26 and in combination with lomustine in glioblastoma,27 carboplatin and paclitaxel in cervical cancer28 and gefitinib in solid tumours.29 Placebo-controlled studies in colorectal cancer,30 renal cell cancer,31 and breast cancer32 confirmed that a reduction in VEGFR2 was due to cediranib and was independent of the companion therapies (primarily a combination with chemotherapy, as in this study).